Q2 2024 Earnings Estimate for bluebird bio, Inc. Issued By William Blair (NASDAQ:BLUE)

bluebird bio, Inc. (NASDAQ:BLUE) – Equities researchers at William Blair lifted their Q2 2024 EPS estimates for bluebird bio in a research note issued to investors on Tuesday, September 24th. William Blair analyst S. Corwin now forecasts that the biotechnology company will post earnings per share of ($0.41) for the quarter, up from their previous estimate of ($0.63). The consensus estimate for bluebird bio’s current full-year earnings is ($1.57) per share. William Blair also issued estimates for bluebird bio’s Q3 2024 earnings at ($0.39) EPS, Q4 2024 earnings at ($0.43) EPS, FY2024 earnings at ($1.58) EPS, Q1 2025 earnings at ($0.25) EPS, Q2 2025 earnings at ($0.05) EPS, Q3 2025 earnings at $0.01 EPS, Q4 2025 earnings at ($0.51) EPS and FY2025 earnings at ($0.80) EPS.

Several other research firms have also issued reports on BLUE. Barclays reduced their price target on shares of bluebird bio from $8.00 to $4.00 and set an “overweight” rating on the stock in a research report on Thursday, August 15th. Bank of America reduced their price target on shares of bluebird bio from $4.00 to $3.00 and set a “buy” rating on the stock in a research report on Thursday, August 15th. Robert W. Baird reduced their price target on shares of bluebird bio from $7.00 to $6.00 and set an “outperform” rating on the stock in a research report on Thursday, August 15th. Royal Bank of Canada reiterated a “sector perform” rating and set a $4.00 price target on shares of bluebird bio in a research report on Thursday, August 15th. Finally, Wells Fargo & Company reduced their price target on shares of bluebird bio from $3.00 to $2.00 and set an “equal weight” rating on the stock in a research report on Wednesday. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, bluebird bio presently has an average rating of “Hold” and a consensus target price of $4.63.

bluebird bio Stock Performance

NASDAQ BLUE opened at $0.50 on Friday. The company has a current ratio of 0.93, a quick ratio of 0.82 and a debt-to-equity ratio of 0.20. The firm has a market capitalization of $55.15 million, a price-to-earnings ratio of -0.68 and a beta of 0.75. The firm’s 50 day simple moving average is $0.76 and its 200 day simple moving average is $0.96. bluebird bio has a 1 year low of $0.46 and a 1 year high of $5.53.

Hedge Funds Weigh In On bluebird bio

A number of hedge funds have recently modified their holdings of BLUE. Ghisallo Capital Management LLC acquired a new position in shares of bluebird bio during the fourth quarter worth $4,347,000. Vestal Point Capital LP bought a new position in bluebird bio during the fourth quarter worth $2,967,000. Vanguard Group Inc. raised its stake in bluebird bio by 19.6% during the first quarter. Vanguard Group Inc. now owns 10,498,460 shares of the biotechnology company’s stock worth $13,438,000 after buying an additional 1,723,081 shares during the last quarter. HBK Investments L P bought a new position in bluebird bio during the fourth quarter worth $2,070,000. Finally, AQR Capital Management LLC raised its stake in bluebird bio by 315.3% during the second quarter. AQR Capital Management LLC now owns 1,334,519 shares of the biotechnology company’s stock worth $1,223,000 after buying an additional 1,013,144 shares during the last quarter. Institutional investors and hedge funds own 87.43% of the company’s stock.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.